NCT00851877 · OUTCOME

Phase I Maximum Tolerated Dose of Nab-Paclitaxel

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer · Source last updated 2020-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg/m^2
Interval / dispersion: Not reported
Time frame: 90 days

What was measured

Seven participants were assigned nab-paclitaxel in dose of 25mg/m\^2. Five participants were assigned nab-paclitaxel in dose of 20mg/m\^2.

Analysis population: 12 patients enrolled in the phase I study.

Groups in this outcome

Phase I Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy

Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor Cisplatin: Cisplatin is an anti-cancer chemotherapy drug Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation intensity-modulated radiation therapy: intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Phase I Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy	12

Reported measurements

Source class 1

Values in mg/m^2 · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Phase I Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy	20	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
20

denoms

counts
group Id
OG000
value
12
units
Participants

description

Seven participants were assigned nab-paclitaxel in dose of 25mg/m\^2. Five participants were assigned nab-paclitaxel in dose of 20mg/m\^2.

groups

description
Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor Cisplatin: Cisplatin is an anti-cancer chemotherapy drug Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation intensity-modulated radiation therapy: intensity-modulated radiation therapy
id
OG000
title
Phase I Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy

param Type

NUMBER

population Description

12 patients enrolled in the phase I study.

reporting Status

POSTED

time Frame

90 days

title

Phase I Maximum Tolerated Dose of Nab-Paclitaxel

type

PRIMARY

unit Of Measure

mg/m^2

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice